COMP <GO>
CMMB vs ENSC // EV/EBITDA & P/E VALUATION
Chemomab Therapeutics Ltd. (NASDAQ) VS. Ensysce Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: CMMB 1
— ENSC 1
■ METRIC PARITY
LAST: $1.09 (-0.91%) • MKT CAP: $8.8M
valuation
—
LAST: $0.44 (-3.16%) • MKT CAP: $8.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CMMB VS. ENSC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CMMB | ENSC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -2.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 40.2 | -3.84 | ENSC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.8M | $8.5M | $250.9K | CMMB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CMMB REV | ENSC REV | CMMB GROSS % | ENSC GROSS % | CMMB FCF | ENSC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $5.1M | — | — | -$11.1M | -$7.9M |
| FY 2024 | $0 | $5.2M | — | — | -$15.4M | -$7.5M |
| FY 2023 | $0 | $2.2M | — | — | -$23.6M | -$10.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CMMB // BETA —
ENSC // BETA —